-
公开(公告)号：WO2009095399A2
公开(公告)日：2009-08-06
申请号：PCT/EP2009/050931
申请日：2009-01-28
Applicant: BIOVITRUM AB (publ) , JENMALM JENSEN, Annika , LEHMANN, Fredrik , NILSSON, Björn, M. , NORDLING, Erik , PARROW, Vendela
Inventor： JENMALM JENSEN, Annika , LEHMANN, Fredrik , NILSSON, Björn, M. , NORDLING, Erik , PARROW, Vendela
IPC: C07D241/20 , C07D401/04 , C07D401/14 , C07D403/12 , C07D417/14 , A61K31/497 , A61K31/4965 , A61K31/5415 , A61P35/00 , A61P17/00 , C07D407/14 , C07D409/14
CPC classification number: A61K31/497 , A61K31/4965 , C07D241/20 , C07D401/04 , C07D401/14 , C07D403/12 , C07D405/14 , C07D409/14 , C07D417/14
Abstract: The present invention relates to compounds of the general formula (I) wherein R 1 , R 2 and R 3 are as defined herein, which can act as inhibitors of protein kinases, specially the Fms-like tyrosine kinase 3 (FLT3). The invention also relates to the use of the compounds in therapy, pharmaceutical compositions comprising the compounds and the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of hematological malignancies, such as AML, MLL, T-ALL, B-ALL and CMML, myeloproliferative disorders, other proliferative disorders like cancer, autoimmune disorders and skin disorders like psoriasis and atopic dermatitis.
Abstract translation: 本发明涉及通式（I）的化合物，其中R 1，R 2和R 3如本文所定义，其可以作为蛋白激酶的抑制剂，特别是Fms样酪氨酸激酶3（FLT3）。 本发明还涉及该化合物在治疗中的用途，包含该化合物的药物组合物和该化合物在制备用于预防和治疗血液恶性肿瘤的药物中的用途，所述药物包括AML，MLL，T-ALL，B -ALL和CMML，骨髓增生性疾病，其他增殖性疾病如癌症，自身免疫性疾病和皮肤病，如牛皮癣和特应性皮炎。
-
公开(公告)号：WO2006067063A2
公开(公告)日：2006-06-29
申请号：PCT/EP2005/056694
申请日：2005-12-12
Applicant: BIOVITRUM AB , PARROW, Vendela , BERGQUIST, Lars, Olof , DREIFELDT, Catrine , FLODIN, Christine
Inventor： PARROW, Vendela , BERGQUIST, Lars, Olof , DREIFELDT, Catrine , FLODIN, Christine
CPC classification number: G01N33/5035 , G01N33/6863 , G01N33/74
Abstract: The present invention relates to methods for the identification of modulators of cytokine class I receptors by determining whether a compound that binds to a cytokine class I receptor at a site different from the binding site of the naturally-occurring cytokine ligand is effective at modulating the amount of the cytokine class I receptor on the surface of the cell.
Abstract translation: 本发明涉及通过确定在与天然存在的细胞因子配体的结合位点不同的位点结合细胞因子I类受体的化合物是否有效调节细胞因子I类受体的调节剂量的方法 的细胞因子I受体在细胞表面。
-
公开(公告)号：WO2009095399A3
公开(公告)日：2009-10-01
申请号：PCT/EP2009050931
申请日：2009-01-28
Applicant: AKINION PHARMACEUTICALS AB , JENMALM JENSEN ANNIKA , LEHMANN FREDRIK , NILSSON BJOERN M , NORDLING ERIK , PARROW VENDELA
Inventor： JENMALM JENSEN ANNIKA , LEHMANN FREDRIK , NILSSON BJOERN M , NORDLING ERIK , PARROW VENDELA
IPC: C07D241/20 , A61K31/4965 , A61K31/497 , A61K31/5415 , A61P17/00 , A61P35/00 , C07D401/04 , C07D401/14 , C07D403/12 , C07D407/14 , C07D409/14 , C07D417/14
CPC classification number: A61K31/497 , A61K31/4965 , C07D241/20 , C07D401/04 , C07D401/14 , C07D403/12 , C07D405/14 , C07D409/14 , C07D417/14
Abstract: The present invention relates to compounds of the general formula (I) wherein R1, R2 and R3 are as defined herein, which can act as inhibitors of protein kinases, specially the Fms-like tyrosine kinase 3 (FLT3). The invention also relates to the use of the compounds in therapy, pharmaceutical compositions comprising the compounds and the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of hematological malignancies, such as AML, MLL, T-ALL, B-ALL and CMML, myeloproliferative disorders, other proliferative disorders like cancer, autoimmune disorders and skin disorders like psoriasis and atopic dermatitis.
Abstract translation: 本发明涉及通式（I）的化合物，其中R 1，R 2和R 3如本文所定义，其可以作为蛋白激酶的抑制剂，特别是Fms样酪氨酸激酶3（FLT3）。 本发明还涉及该化合物在治疗中的用途，包含该化合物的药物组合物和该化合物在制备用于预防和治疗血液恶性肿瘤的药物中的用途，所述药物包括AML，MLL，T-ALL，B -ALL和CMML，骨髓增生性疾病，其他增殖性疾病如癌症，自身免疫性疾病和皮肤病，如牛皮癣和特应性皮炎。
-
Patent Agency Ranking4.发明申请
公开(公告)号：WO2006067063A3
公开(公告)日：2007-01-25
申请号：PCT/EP2005056694
申请日：2005-12-12
Applicant: BIOVITRUM AB , PARROW VENDELA , BERGQUIST LARS OLOF , DREIFELDT CATRINE , FLODIN CHRISTINE
Inventor： PARROW VENDELA , BERGQUIST LARS OLOF , DREIFELDT CATRINE , FLODIN CHRISTINE
CPC classification number: G01N33/5035 , G01N33/6863 , G01N33/74
Abstract: The present invention relates to methods for the identification of modulators of cytokine class I receptors by determining whether a compound that binds to a cytokine class I receptor at a site different from the binding site of the naturally-occurring cytokine ligand is effective at modulating the amount of the cytokine class I receptor on the surface of the cell.
Abstract translation: 本发明涉及通过确定在与天然存在的细胞因子配体的结合位点不同的位点结合细胞因子I类受体的化合物是否有效调节细胞因子I类受体的调节剂量的方法 的细胞因子表面I类受体。
-
公开(公告)号：WO2005001478A1
公开(公告)日：2005-01-06
申请号：PCT/SE2004/001039
申请日：2004-06-28
Applicant: BIOVITRUM AB , PARROW, Vendela , MORÉUS, Lotta
Inventor： PARROW, Vendela , MORÉUS, Lotta
IPC: G01N33/569
CPC classification number: G01N33/74 , C07K16/2869 , G01N33/6863 , G01N2500/00
Abstract: The present invention relates to methods for identifying agents that modulate the effect of cytokine class I receptor binding compounds, by inhibiting the interaction between the cytokine class I receptor and nuclear factors. The agents are useful for decreasing IGF-1 levels in a cell, and for the treatment of medical disorders caused by hormone dysregulation, such as growth hormone or prolactin dysregulation.
Abstract translation: 本发明涉及通过抑制细胞因子I类受体和核因子之间的相互作用来鉴定调节细胞因子I类受体结合化合物的作用的试剂的方法。 这些药剂可用于降低细胞中的IGF-1水平，并且用于治疗由激素失调引起的医学障碍，例如生长激素或催乳素失调。
-
公开(公告)号：WO02097390A8
公开(公告)日：2004-06-24
申请号：PCT/SE0201056
申请日：2002-05-31
Applicant: BIOVITRUM AB , PARROW VENDELA , ROSENGREN LINDA
Inventor： PARROW VENDELA , ROSENGREN LINDA
CPC classification number: C12Q1/6834 , C12Q2563/131 , C12Q2545/113
Abstract: The invention provides a quantitative hybridization assay for the analysis of mRNA in a target nucleic acid sample. The method comprising the steps of (i) immobilizing the target nucleic acid sample on a solid support; (ii) contacting a labeled antisense probe to a first portion of the said target nucleic acid sample, and a labeled sense probe to a second portion of the said target nucleic acid sample; (iii) detecting and quantitating the signals generated from hybridized antisense probe and hybridized sense probe; and (iv) determining the value represented by the antisense probe signal minus the sense probe signal, said value being proportional to the amount of mRNA in the target nucleic acid sample.
Abstract translation: 本发明提供了用于分析靶核酸样品中的mRNA的定量杂交测定法。 该方法包括以下步骤：（i）将靶核酸样品固定在固体支持物上; （ii）将标记的反义探针与所述靶核酸样品的第一部分接触，将标记的有义探针与所述靶核酸样品的第二部分接触; （iii）检测和定量由杂交的反义探针和杂交的感测探针产生的信号; 和（iv）确定由反义探针信号表示的值减去感测探针信号，所述值与靶核酸样品中mRNA的量成比例。
-
公开(公告)号：WO2002097390A3
公开(公告)日：2002-12-05
申请号：PCT/SE2002/001056
申请日：2002-05-31
Applicant: BIOVITRUM AB , PARROW, Vendela , ROSENGREN, Linda
Inventor： PARROW, Vendela , ROSENGREN, Linda
IPC: C12Q1/68
Abstract: The invention provides a quantitative hybridization assay for the analysis of mRNA in a target nucleic acid sample. The method comprising the steps of (i) immobilizing the target nucleic acid sample on a solid support; (ii) contacting a labeled antisense probe to a first portion of the said target nucleic acid sample, and a labeled sense probe to a second portion of the said target nucleic acid sample; (iii) detecting and quantitating the signals generated from hybridized antisense probe and hybridized sense probe; and (iv) determining the value represented by the antisense probe signal minus the sense probe signal, said value being proportional to the amount of mRNA in the target nucleic acid sample.
-
公开(公告)号：WO02097390A2
公开(公告)日：2002-12-05
申请号：PCT/SE0201056
申请日：2002-05-31
Applicant: BIOVITRUM AB , PARROW VENDELA , ROSENGREN LINDA
Inventor： PARROW VENDELA , ROSENGREN LINDA
CPC classification number: C12Q1/6834 , C12Q2563/131 , C12Q2545/113
Abstract: The invention provides a quantitative hybridization assay for the analysis of mRNA in a target nucleic acid sample. The method comprising the steps of (i) immobilizing the target nucleic acid sample on a solid support; (ii) contacting a labeled antisense probe to a first portion of the said target nucleic acid sample, and a labeled sense probe to a second portion of the said target nucleic acid sample; (iii) detecting and quantitating the signals generated from hybridized antisense probe and hybridized sense probe; and (iv) determining the value represented by the antisense probe signal minus the sense probe signal, said value being proportional to the amount of mRNA in the target nucleic acid sample.
Abstract translation: 本发明提供了用于分析靶核酸样品中的mRNA的定量杂交测定法。 该方法包括以下步骤：（i）将靶核酸样品固定在固体支持物上; （ii）将标记的反义探针与所述靶核酸样品的第一部分接触，将标记的有义探针与所述靶核酸样品的第二部分接触; （iii）检测和定量由杂交的反义探针和杂交的感测探针产生的信号; 和（iv）确定由反义探针信号表示的值减去感测探针信号，所述值与靶核酸样品中mRNA的量成比例。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.01 seconds)
